Defining and Managing the Preanalytical Phase With FMECA: Automation and/or "Human" Control.

health-information technology (HIT) human systems integration medical devices and technologies patient safety process control safety culture and behavior change

Journal

Human factors
ISSN: 1547-8181
Titre abrégé: Hum Factors
Pays: United States
ID NLM: 0374660

Informations de publication

Date de publication:
02 2020
Historique:
pubmed: 17 9 2019
medline: 28 5 2021
entrez: 17 9 2019
Statut: ppublish

Résumé

Our scope is to provide methodological elements on how to manage effectively the preanalytical phase in the laboratory testing process, by objectively measuring the risk connected to the phases handled by man with respect to those managed by machines. Preanalytical errors account for most of the mistakes related to laboratory testing and can affect patient care. Hence, it is necessary to manage the risk connected to the preanalytical phase, as required by certification and accreditation bodies. The risk assessment discloses the steps at greater risk and gives indications to make decisions. We have reviewed the state of art in the automation of the preanalytical phase, addressing needs and problems. We have used the proactive risk assessment methodology FMECA (Failure Mode, Effects, and Criticality Analysis) to identify the most critical phases in our preanalytical process and have calculated the risk associated. The most critical phases were the human controlled ones. In particular, the highest risk indexes were associated to manual acceptance of test orders, identification of the patients, tube labeling, and sample collection. Automation in the preanalytical phase is fundamental to replace, support, or extend the human contribution. Nevertheless each organization is different about workloads and competencies, so the most suitable management must be tailor-made in each context. We present a method by which each organization is able to find its best balance between automation and human contribution in the control of the preanalytical phase.

Sections du résumé

OBJECTIVE
Our scope is to provide methodological elements on how to manage effectively the preanalytical phase in the laboratory testing process, by objectively measuring the risk connected to the phases handled by man with respect to those managed by machines.
BACKGROUND
Preanalytical errors account for most of the mistakes related to laboratory testing and can affect patient care. Hence, it is necessary to manage the risk connected to the preanalytical phase, as required by certification and accreditation bodies. The risk assessment discloses the steps at greater risk and gives indications to make decisions.
METHOD
We have reviewed the state of art in the automation of the preanalytical phase, addressing needs and problems. We have used the proactive risk assessment methodology FMECA (Failure Mode, Effects, and Criticality Analysis) to identify the most critical phases in our preanalytical process and have calculated the risk associated.
RESULTS
The most critical phases were the human controlled ones. In particular, the highest risk indexes were associated to manual acceptance of test orders, identification of the patients, tube labeling, and sample collection.
CONCLUSION
Automation in the preanalytical phase is fundamental to replace, support, or extend the human contribution. Nevertheless each organization is different about workloads and competencies, so the most suitable management must be tailor-made in each context.
APPLICATION
We present a method by which each organization is able to find its best balance between automation and human contribution in the control of the preanalytical phase.

Identifiants

pubmed: 31525072
doi: 10.1177/0018720819874906
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-36

Auteurs

Claudia Bellini (C)

9313 University Hospital of Siena, Italy.

Roberto Guerranti (R)

9313 University Hospital of Siena, Italy.

Francesca Cinci (F)

9313 University Hospital of Siena, Italy.

Eva Milletti (E)

9313 University of Siena, Italy.

Carlo Scapellato (C)

161157 University Hospital of Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH